[ad_1]
Beximco Prescription drugs Restricted has modified the identify of the lately acquired subsidiary, Sanofi Bangladesh Restricted, to Synovia Pharma PLC, efficient from Friday.
Sanofi Bangladesh Restricted was a part of the worldwide biopharmaceutical firm Sanofi SA earlier than the acquisition of a majority stake within the firm (54.6%) by Beximco Pharma on 1 October 2021.
The change of identify has been made in compliance with the phrases of the Share Buy Settlement between the Firm and the Sellers, stated Beximco in a press launch at present.
The identify “Synovia” is derived from the French phrase Synergie, that means “collaboration” and the Latin phrase Through, that means “path”.
Synovia Pharma will proceed to fabricate, market and import Sanofi SA merchandise, making certain continued provide for sufferers in Bangladesh throughout therapeutic areas similar to cardiology, diabetes, oncology, dermatology and CNS, the press assertion added.
Managing Director of Beximco Pharma Nazmul Hassan stated, “Following the acquisition of a majority stake in Sanofi Bangladesh, we now have been targeted on integrating its individuals and merchandise. By renaming the enterprise Synovia Pharma, we mark the following thrilling step on this transition. Underneath this new identify, we’re dedicated to sustaining Synovia Pharma’s established popularity for high-quality merchandise and to delivering inexpensive therapies and breakthrough therapies to the rising market in Bangladesh.
“We’re additionally excited to maximise the potential of Beximco Pharma’s strengthened place in key therapeutic areas to drive long-term development,” he added.
[ad_2]
Source link
